Vir Biotechnology Inc (VIR)

Mar 31, 2025

Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution - simplywall.st

Mar 31, 2025

Mar 28, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo Finance

Mar 28, 2025

Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India

Mar 26, 2025

Mar 24, 2025

(VIR) Trading Advice - news.stocktradersdaily.com

Mar 24, 2025

Mar 21, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow

Mar 21, 2025

Mar 13, 2025

(VIR) Trading Signals - Stock Traders Daily

Mar 13, 2025

Mar 13, 2025

Morgan Stanley maintains $20 target on Vir Biotechnology stock By Investing.com - Investing.com Canada

Mar 13, 2025

Mar 13, 2025

Morgan Stanley maintains $20 target on Vir Biotechnology stock - Investing.com India

Mar 13, 2025

Mar 13, 2025

Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection - Marketscreener.com

Mar 13, 2025

Mar 13, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial -March 13, 2025 at 08:30 am EDT - Marketscreener.com

Mar 13, 2025

Mar 13, 2025

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire

Mar 13, 2025

Mar 11, 2025

Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus

Mar 11, 2025

Mar 11, 2025

SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 11, 2025

Mar 07, 2025

Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $35.67 - Defense World

Mar 07, 2025

Mar 05, 2025

Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN

Mar 05, 2025

Mar 05, 2025

Principal Financial Group Inc. Has $3.28 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025

Mar 05, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund - Defense World

Mar 05, 2025

Mar 05, 2025

Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025

Mar 04, 2025

Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha

Mar 04, 2025

Mar 03, 2025

Vir Biotechnology's (VIR) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Mar 03, 2025

Mar 03, 2025

What is HC Wainwright’s Forecast for VIR Q1 Earnings? - Defense World

Mar 03, 2025

Mar 02, 2025

(VIR) On The My Stocks Page - Stock Traders Daily

Mar 02, 2025

Mar 02, 2025

HC Wainwright Reaffirms “Buy” Rating for Vir Biotechnology (NASDAQ:VIR) - Defense World

Mar 02, 2025

Mar 02, 2025

Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating - TipRanks

Mar 02, 2025

Mar 02, 2025

Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, Barclays Analyst Says - Defense World

Mar 02, 2025

Mar 01, 2025

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Canada Finance

Mar 01, 2025

Feb 28, 2025

7 Analysts Have This To Say About Vir Biotechnology - Benzinga

Feb 28, 2025

Feb 28, 2025

Decoding Vir Biotechnology Inc (VIR): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025

Feb 27, 2025

Vir Biotechnology’s Transformative Year: Earnings Call Insights - TipRanks

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology Becomes Oversold (VIR) - Nasdaq

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock By Investing.com - Investing.com Canada

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock - Investing.com India

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

Feb 27, 2025

Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology - TipRanks

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology: Balancing Long-term Potential with Near-term Uncertainty – A Hold Rating Analysis - TipRanks

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology, Inc. SEC 10-K Report - TradingView

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates - MSN

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - BioSpace

Feb 27, 2025

Feb 26, 2025

Vir Biotechnology Reports 2024 Financial Results and Strategic Advances - TipRanks

Feb 26, 2025

Feb 26, 2025

Vir Biotechnology: Strong Financial Position and Promising Pipeline Justify Buy Rating - TipRanks

Feb 26, 2025

Feb 26, 2025

Earnings call transcript: Vir Biotech beats Q4 2024 forecasts, stock rises - Investing.com India

Feb 26, 2025

Feb 26, 2025

Vir Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 26, 2025

Feb 26, 2025

Vir Biotechnology reports Q4 EPS (76c), consensus (87c) - TipRanks

Feb 26, 2025

Feb 26, 2025

Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 11c - StreetInsider.com

Feb 26, 2025

Feb 25, 2025

Vir Biotechnology CEO sells $152,407 in stock By Investing.com - Investing.com South Africa

Feb 25, 2025

Feb 25, 2025

Vir Biotechnology's SVP sells shares worth $14,766 By Investing.com - Investing.com Canada

Feb 25, 2025